Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alzyn is a patented nutraceutical supplement developed by Alzyn Pharmaceuticals (Alzyn LLC) in collaboration with the Florida State University College of Medicine. The formulation is a combination of Vitamin B-12, epigallocatechin gallate (EGCG), melatonin, and resveratrol, designed to support brain health, enhance immunity, and improve sleep quality. It is specifically marketed to combat memory loss through a nutrigenomics approach. While the company initially focused on a transdermal delivery system to address malabsorption issues in older populations, an oral formulation was subsequently developed in partnership with Young Living Essential Oils. The product is positioned as a science-based dietary supplement rather than a traditional pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alzyn.